AstraZeneca launches and prices a debut GBP 350 million sterling bond and a EUR 750 million eurobond

Not for release, publication or distribution directly or indirectly in or into
the United States, Canada, Australia or Japan


AstraZeneca launches and prices a debut GBP 350 million sterling bond and a EUR
750 million eurobond

AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard &
Poor's, announces the successful pricing of a debut sterling bond for GBP 350
million and a Euro 750 million eurobond transaction (the “Bonds”).  The proceeds
of the issue will be used for general corporate purposes and to repay a portion
of the outstanding US commercial paper taken on in connection with the
acquisition of MedImmune.
Both transactions were issued under AstraZeneca PLC's Euro Medium Term Note
(EMTN) programme.  The sterling bond is a GBP 350 million, fixed rate issue with
a coupon of 5.75% maturing 13 November 2031.  The eurobond is a EUR 750 million,
fixed rate issue with a coupon of 4.625% maturing12 November 2010.
This transaction represents a continuation of the refinancing of the acquisition
of MedImmune Inc, following the $6.9 billion, 4-tranche SEC Global and EUR 750
million debut eurobond transactions in September.

The Bonds will be issued to institutional investors outside the US in accordance
with Regulation S of the U.S. Securities Act of 1933, as amended.  The Bonds
will be admitted to listing on the UKLA's Official List and to trading on the
London Stock Exchange's Fixed Interest and Gilt Edged Market.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world's leading
bio-pharmaceutical companies with healthcare sales of $26.47 billion and leading
positions in sales of gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infection products. AstraZeneca is listed in the Dow
Jones Sustainability Index (Global) as well as the FTSE4Good Index.

7 November 2007

Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Karl Hard, Tel: +44 (0) 207 304 5322
Jorgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065
Pete Vozzo, (MedImmune) Tel: + 1 301-398-4358

This announcement is for information only and does not constitute an offer or
invitation to subscribe for or purchase any securities.

The securities have not been, nor will they be, registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), and no securities
shall be offered or sold in the United States or to U.S. persons (as those terms
are defined in Regulation S under the Securities Act) absent registration or an
applicable exemption from the registration requirements of the Securities Act. 
There will be no public offering of the securities in the United States in
connection with this transaction.